SCHEMBL16664284

SCHEMBL16664284

CC(C)(C)OC(=O)Nc1cc(C2CCN(c3ccc(C#N)cn3)CC2)n[nH]1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.45
PANK3 Q9H999 4/20 0.44
LCAT P04180 1/20 0.44
CNR2 P34972 1/20 0.42
EGLN2 Q96KS0 1/20 0.41
HSD11B1 P28845 1/20 0.41
AR P10275 1/20 0.41
RET P07949 1/20 0.41
CHRM4 P08173 3/20 0.41
GPR119 Q8TDV5 1/20 0.40
JAK2 O60674 2/20 0.40
JAK1 P23458 2/20 0.40
JAK3 P52333 2/20 0.40
KCNH2 Q12809 2/20 0.40
CHRM2 P08172 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
TIPARP Q7Z3E1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16648646 0.86 FASN (0.49) FASNPANK3LCATHSD11B1CHRM4
SCHEMBL7078845 0.78 RET (0.57) PANK3RETCHRM4GPR119JAK2
SCHEMBL16664272 0.75 PLAT (0.38) CHRM1
SCHEMBL16664264 0.75 LCAT (0.46) FASNPANK3LCATHSD11B1GPR119
SCHEMBL952010 0.75 JAK3 (0.58) RETJAK3
SCHEMBL16649038 0.73 MALT1 (0.50) PANK3LCATCNR2CHRM4
SCHEMBL21522618 0.72 CHRM2 (0.53) PANK3RETCHRM4JAK2JAK1
SCHEMBL7660140 0.72 GPR119 (0.67) PANK3GPR119
SCHEMBL26582234 0.72 GRM4 (0.52) PANK3RETCHRM4JAK3
SCHEMBL30546199 0.72 GRM4 (0.52) PANK3RETCHRM4JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
EP-2862861-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 FASN 1282/4885PANK3 1183/4885LCAT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.